Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

475.85 +2.65 (+0.56%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022

April 27, 2022

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation

April 06, 2022

From United Therapeutics Corporation

Via Business Wire

First Human With Pig Heart Transplant Dies: Reuters ↗

March 09, 2022

A 57-year-old man with terminal heart disease who became the first person to receive a genetically modified pig's heart has died, the University of Maryland Medical...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

February 28, 2022

Barclays cut the price target on MasTec, Inc. (NYSE: MTZ) from $140 to $120. MasTec shares fell 0.1% to $79.00 in pre-market trading.

Via Benzinga

Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease

February 28, 2022

PH-ILD is a rare, serious, and progressive illness without an approved treatment in Europe and many other parts of the world

Via Newswire.com

United Therapeutics Earnings Perspective: Return On Capital Employed ↗

February 25, 2022

Pulled from Benzinga Pro data, United Therapeutics (NASDAQ:UTHR) posted Q4 earnings of $112.20 million, an increase from Q3 of 31.04%. Sales dropped to $415.20 million, a 6.63%...

Via Benzinga

FDA Pushes United Therapeutics-MannKind Tyvaso DPI's Decision Date; United Therapeutics' Q4 Misses Consensus ↗

February 24, 2022

United Therapeutics Corp (NASDAQ: UTHR) and its partner MannKind Corp (NASDAQ: MNKD) have received an FDA information request letter for additional...

Via Benzinga

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results

February 24, 2022

From United Therapeutics Corporation

Via Business Wire

United Therapeutics's Earnings Outlook ↗

February 23, 2022

United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022

February 21, 2022

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces Historic Achievements in its Xenotransplantation Programs

January 21, 2022

From United Therapeutics Corporation

Via Business Wire

First Successful Pig Heart Transplant Into Human: Details On The Amazing Technology And A Public Company To Watch ↗

January 11, 2022

Pigs may not be able to fly, but they've provided a vital organ in a life-saving surgery for one U.S. man. What Happened: A Maryland hospital completed the first...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 11, 2022

Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

7 Pharmaceutical Stocks That Could Make You Rich ↗

January 06, 2022

Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich

Via InvestorPlace

Mark To Market ↗

January 02, 2022

I thought that I would have a look at my own financial performance in 2021. In preview, I did alright, but not as well as the market. Let's take a look at what my portfolio held and how well it did.

Via Talk Markets

United Therapeutics Corporation to Webcast Executive Fireside Chat Conversation With J.P. Morgan Analyst

December 30, 2021

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022

December 03, 2021

From United Therapeutics Corporation

Via Business Wire

Liquidia's Inhaled Treprostinil Powder Scores Tentative FDA Approval For PAH ↗

November 08, 2021

The FDA has granted tentative approval to Liquidia Corporation's (NASDAQ: LQDA) Yutrepia (treprostinil) inhalation powder for pulmonary arterial...

Via Benzinga

United Therapeutics Corporation (UTHR) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

UTHR earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

Recap: United Therapeutics Q3 Earnings ↗

November 03, 2021

United Therapeutics (NASDAQ:UTHR) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗

November 02, 2021

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...

Via Benzinga

Why Shares of MannKind Corporation Are Falling This Morning ↗

October 18, 2021

Investors are hyperventilating after a delay for its inhaled medicine.

Via The Motley Fool

FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease ↗

October 18, 2021

The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary...

Via Benzinga

Earnings Scheduled For November 3, 2021 ↗

November 03, 2021

Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

Acceleron Stock Heats Up On $11 Billion Takeover Rumor; So, Who's The Buyer? ↗

September 27, 2021

A biotech working in lung and blood diseases, as well as cancer, could be acquired.

Via Investor's Business Daily

United Therapeutics-MannKind's Formulated Tyvaso Shows Benefit In Pulmonary Hypertension Patients ↗

September 07, 2021

United Therapeutics Corporation (NASDAQ: UTHR) has presented new clinical data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary...

Via Benzinga

Innovators in Pharma Sectors See Potential, Promise in Providing Improved Treatments

August 05, 2021

Via FinancialNewsMedia

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

United Therapeutics Corporation - Common Stock (NQ:UTHR)

All News about United Therapeutics Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today